Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc., a Delaware corporation, on November 13, 2025. The filing serves as a Regulation FD disclosure regarding the release of an updated investor presentation (the "Investor Deck") on the Company's website.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report is a disclosure of non-financial corporate information rather than a financial results announcement.
Material Changes and Operational Updates
The primary material update disclosed in this filing is the release of an updated Investor Deck detailing recent progress in the Company's ongoing product development programs. Specific areas of progress include:
- nPulse Vybrance Percutaneous Electrode
- nPulse Cardiac Clamp
- nPulse Cardiac Catheter
The Company intends to use this presentation for communications with investors and analysts.
Guidance, Outlook, and Risks
The filing explicitly states that the Investor Deck contains forward-looking statements subject to risks and uncertainties. These risks are referenced as being set forth in the Company's other SEC filings. The Company undertakes no obligation to publicly update or revise the information in the Investor Deck except as required by law.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Investor Deck) for specific details on product development milestones.
- Verify the Company's latest financial position by consulting the most recent 10-K or 10-Q filings, as this 8-K contains no financial statements.
- Assess the risks associated with the forward-looking statements regarding the nPulse product line as detailed in the Company's periodic reports.
- Confirm the trading status of Common Stock (Symbol: PLSE) on The Nasdaq Stock Market.